Remarkable response of nivolumab‐refractory lung cancer to salvage chemotherapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1759-7714|9|1|175-180

ISSN： 1759-7706

Source： Thoracic Cancer, Vol.9, Iss.1, 2018-01, pp. : 175-180

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab

By  

Thoracic Cancer, Vol. 9, Iss. 1, 2018-01 ,pp. : 164-166

John Wiley & Sons Inc

Access to resources Recommend Favorite

Promising effects of 3rd line cyclophosphamide, adriamycin and vincristine (CAV) and 4th line ifosfamide and carboplatin chemotherapy in refractory small cell lung cancer

By  

Thoracic Cancer, Vol. 6, Iss. 5, 2015-09 ,pp. : 659-663

John Wiley & Sons Inc

Access to resources Recommend Favorite

Does the response to induction chemotherapy impact the timing of thoracic radiotherapy for limited‐stage small‐cell lung cancer?

By  

Thoracic Cancer, Vol. 6, Iss. 5, 2015-09 ,pp. : 605-612

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evolution of induction chemotherapy for non‐small cell lung cancer over the last 30 years: A surgical appraisal

By  

Thoracic Cancer, Vol. 6, Iss. 6, 2015-11 ,pp. : 731-740

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of chemotherapy for newly diagnosed advanced non‐small cell lung cancer with venous thromboembolism

By  

Thoracic Cancer, Vol. 6, Iss. 6, 2015-11 ,pp. : 772-777

John Wiley & Sons Inc

Access to resources Recommend Favorite